Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Systemic Lupus Erythematosus

Subcutaneous Belimumab Improves Systemic Lupus Srythematosus Outcomes

Reuters Staff  |  May 1, 2018

NEW YORK (Reuters Health)—Subcutaneous belimumab improves outcomes in anti-dsDNA-positive hypocomplementemic patients with systemic lupus erythematosus (SLE), according to results from a Phase 3 randomized, controlled trial. Intravenous belimumab is approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of patients with active, autoantibody-positive SLE who are receiving standard…

New Study Examines Treatment Options for Incomplete Lupus Erythematous

Catherine Kolonko  |  April 26, 2018

A recent study explored medical concerns for patients who have lupus markers, but fall short of meeting enough criteria for official disease classification. Investigators at the Oklahoma Medical Research Foundation conducted a large study to explore current treatments of patients with incomplete lupus erythematous (ILE) and to compare antibody characteristics to healthy people and patients…

Professor Shares Findings from 45 Years of Lupus Research

Susan Bernstein  |  March 18, 2018

SAN DIEGO—What are the predisposing genes that suggest who will develop active systemic lupus erythematosus and who will stay healthy? Decades of research data help rheumatologists clarify this picture, says Argyrios N. Theofilopoulos, MD, professor of immunology and microbiology at Scripps Research Institute in La Jolla, Calif. At his Nov. 5 lecture at the 2017…

SLE Remission: The Treat-to-Target Approach

Susan Bernstein  |  March 17, 2018

SAN DIEGO—Treatment strategies for systemic lupus erythematosus (SLE) have changed a great deal over the years, but progress has been slow and inadequate. According to a 2011 survey, many patients with lupus still report that they have a low quality of life due to their health problems.1 Rheumatologists face the challenge to develop more successful…

Updates on Managing Lupus Complications

Susan Bernstein  |  March 17, 2018

SAN DIEGO—To manage patients with systemic lupus erythematous (SLE), rheuma­tologists must be aware of potentially serious complications affecting many organ systems. On Nov. 7 at the 2017 ACR/ARHP Annual Meeting, two experts offered insights on cardiovascular and hematological complications of lupus. Myocardial Disease in Lupus Lupus patients are at increased risk for heart-related complications, especially…

marekuliasz / shutterstock.com

Diagnostic Challenges of SLE & Celiac Sprue

Leslie Pack Ranken, MD  |  March 17, 2018

Systemic lupus erythematosus (SLE) can present in many ways and can be difficult to diagnose. Its association with celiac sprue has been only rarely documented, but has appeared in several case reports. When presenting together, it can be difficult to distinguish the underlying disease, because SLE itself has been known to cause malabsorption. This case…

Experts Discuss the Latest Precision Medicine Research

Susan Bernstein  |  February 18, 2018

SAN DIEGO—In just two decades, precision medicine has gone from futuristic concept to realistic toolbox for clinical physicians. At the 2017 ACR Clinical Research Conference on Nov. 3, the Precision Medicine in Rheumatic Diseases: Hopes and Challenges lecture featured rheumatologists and experts on genetics, genomics, pharmaco­genetics and big data who spoke about the latest research…

Circulating MicroRNA Provides Clues to Class IV Lupus Nephritis

Lara C. Pullen, PhD  |  January 29, 2018

A recent study has shed light on the role of circulating microRNAs (miRNAs) in SLE pathogenesis. In particular, patients with lupus nephritis have an abundance of 24 miRNAs, many of which play a role in regulatory feedback loops…

Social Media Campaign for Latin Lupus Sufferers

Social Media Campaign for Latin Lupus Sufferers

Vanessa Caceres  |  January 19, 2018

  A person living with lupus may feel isolated. They receive information from their doctor, but it’s never enough to fully understand the disease. So where do they turn? Social media, where they can connect, share information and learn. A new social media initiative, Hablemos de Lupus—which translates to Let’s Talk About Lupus—focuses on sharing…

Tips for Treating Lupus-Related Renal Disease, Pain, Alopecia

Susan Bernstein  |  January 19, 2018

SAN DIEGO—Rheumatologists who treat lupus patients gleaned tips on diagnosis and management of renal disease, painful neuropathies and alopecia at a “Curbside Consults” session held Nov. 6 at the ACR/ARHP Annual Meeting in San Diego. Membranous Lupus Nephritis Patients with refractory membranous lupus nephritis (MLN), or Class V lupus nephritis, face “significant morbidity, most of…

  • « Previous Page
  • 1
  • …
  • 24
  • 25
  • 26
  • 27
  • 28
  • …
  • 45
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences